Insider Selling: Illumina, Inc. (ILMN) SVP Sells $32,672.85 in Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $225.33, for a total transaction of $32,672.85. Following the sale, the senior vice president now directly owns 6,388 shares in the company, valued at $1,439,408.04. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Friday, November 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The shares were sold at an average price of $207.88, for a total transaction of $334,478.92.
  • On Tuesday, October 3rd, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $202.23, for a total transaction of $29,323.35.

Shares of Illumina, Inc. (NASDAQ ILMN) traded up $2.98 during midday trading on Friday, hitting $217.65. 588,430 shares of the stock were exchanged, compared to its average volume of 731,127. The firm has a market cap of $31,341.82, a P/E ratio of 62.77, a P/E/G ratio of 3.55 and a beta of 0.79. Illumina, Inc. has a 1 year low of $121.47 and a 1 year high of $230.72. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.97 EPS. sell-side analysts expect that Illumina, Inc. will post 3.75 earnings per share for the current year.

Several equities research analysts recently issued reports on ILMN shares. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Vetr lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $209.78 price target on the stock. in a report on Thursday, August 31st. Leerink Swann reaffirmed an “outperform” rating and set a $225.00 price target (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Argus lifted their price target on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $200.00 price target on shares of Illumina in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. Illumina presently has an average rating of “Buy” and an average price target of $201.98.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Moors & Cabot Inc. lifted its position in shares of Illumina by 7.1% in the 3rd quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock worth $1,497,000 after purchasing an additional 500 shares during the period. IFM Investors Pty Ltd acquired a new position in shares of Illumina in the 3rd quarter worth approximately $804,000. DF Dent & Co. Inc. lifted its position in shares of Illumina by 4.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock worth $96,917,000 after purchasing an additional 18,741 shares during the period. Neuberger Berman Group LLC lifted its position in shares of Illumina by 10.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 5,384 shares of the life sciences company’s stock worth $1,072,000 after purchasing an additional 491 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Illumina in the 3rd quarter worth approximately $577,000. Hedge funds and other institutional investors own 91.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://weekherald.com/2017/12/09/insider-selling-illumina-inc-ilmn-svp-sells-32672-85-in-stock.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply